XOMA Royalty Acquisition | Healthcare Deal in CA

Ligand Pharmaceuticals has agreed to complete the XOMA Royalty acquisition, a pharmacy business in California, for an undisclosed price. XOMA Royalty holds royalty interests tied to healthcare products, supporting Ligand’s broader pharmacy acquisition strategy and healthcare M&A portfolio in CA acquisitions. The merger acquisition structure is designed to transfer XOMA Royalty’s rights and related obligations into Ligand’s platform, strengthening strategic acquisition positioning in the U.S. healthcare sector. Ligand is pursuing this strategic acquisition as a merger acquisition with an announced status, while regulatory approvals and customary closing conditions are expected to govern timing.